Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Regeneron
Regeneron
FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron
BioSpace
Mon, 08/14/23 - 11:29 am
FDA
Ipsen
Revance Therapeutics
Neurocrine
Regeneron
palovarotene
fibrodysplasia ossificans progressiva
Daxxify
cervical dystonia
Ingrezza
chorea
Huntington's disease
pozelimab
CHAPLE disease
Regeneron's high-dose Eylea shows staying power as company awaits FDA decision
Fierce Pharma
Thu, 08/10/23 - 09:49 pm
Regeneron
Eylea
age-related macular degeneration
FDA
Regeneron adds Decibel to gene therapy playlist, turning up volume on long-running hearing loss collaboration
Fierce Biotech
Wed, 08/9/23 - 10:10 am
Regeneron
hearing loss
Decibel Therapeutics
gene therapy
M&A
Regeneron expects FDA decision on higher-dose Eylea this year
Reuters
Thu, 08/3/23 - 06:40 pm
Regeneron
Eylea
FDA
Moderna, Regeneron post solid earnings, eye a strong finish to 2023
Medical Marketing and Media
Thu, 08/3/23 - 11:23 am
earnings
Moderna Therapeutics
Regeneron
Regeneron rethinks CD28 bispecific R&D plan after 2 patients die
Fierce Biotech
Thu, 08/3/23 - 10:17 am
Regeneron
prostate cancer
clinical trials
patient deaths
REGN5678
bispecific antibodies
5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year
BioSpace
Fri, 07/28/23 - 11:46 am
Ipsen
palovarotene
fibrodysplasia ossificans progressiva
Regeneron
CHAPLE disease
pozelimab
Biomarin
Voxzogo
achondroplasia
Santhera Pharmaceuticals
vamorolone
DMD
Springworks
nirogacestat
desmoid tumors
Scratching the surface of the urticaria pipeline
EP Vantage
Thu, 07/20/23 - 10:00 am
chronic urticaria
Sanofi
Dupixent
Regeneron
Novartis
Roche
Xolair
Allakos
AstraZeneca
Celldex Therapeutics
Dupixent goes back-to-back as top Rx, OTC pharma brand in June
Medical Marketing and Media
Thu, 07/6/23 - 10:16 am
Dupixent
Sanofi
Regeneron
Is Regeneron's Stock in Trouble After This FDA Rejection?
Motley Fool
Thu, 07/6/23 - 10:15 am
Regeneron
Eylea
FDA
Regeneron's high-dose Eylea hit with surprise FDA rejection over manufacturing hiccups
Fierce Pharma
Tue, 06/27/23 - 10:24 pm
Regeneron
Eylea
FDA
Aslan sells Japanese rights to would-be Dupixent rival for $12M
Fierce Biotech
Thu, 06/22/23 - 10:41 pm
Aslan
Dupixent
Japan
eczema
Sanofi
Regeneron
eblasakimab
Dupixent reclaims throne as top Rx, OTC pharma brand in May
Medical Marketing and Media
Tue, 06/6/23 - 11:13 am
Dupixent
Sanofi
Regeneron
DTC advertising
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
Wed, 05/31/23 - 10:51 am
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
ASCO: Regeneron's Opdualag rival records double the historical response rate in melanoma
Fierce Biotech
Thu, 05/25/23 - 08:49 pm
ASCO 2023
Regeneron
advanced melanoma
fianlimab
Sanofi, Regeneron flesh out COPD data with Dupixent
Pharmaphorum
Mon, 05/22/23 - 10:16 am
Sanofi
Regeneron
COPD
Dupixent
Supreme Court rules against Amgen bid to revive cholesterol drug patents
KFGO/Reuters
Thu, 05/18/23 - 11:24 am
Supreme Court
Amgen
Sanofi
Regeneron
patents
Repatha
legal
Regeneron CEO backs FTC’s attempt to block $28B Amgen-Horizon deal
Medical Marketing and Media
Wed, 05/17/23 - 10:48 pm
Amgen
Horizon Therapeutics
FTC
Regeneron
antitrust
M&A
Leonard Schleifer
A blockbuster year could be building
EP Vantage
Wed, 05/10/23 - 09:55 am
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo
Eli Lilly
Gilead Sciences
Horizon Therapeutics
Merck
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
Revenues down for Moderna, up for Regeneron in Q1
Medical Marketing and Media
Thu, 05/4/23 - 10:28 am
Moderna Therapeutics
Regeneron
earnings
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »